• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    2/14/23 4:19:13 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XENE alert in real time by email
    SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, #2
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    (Name of Issuer)

    Xenon Pharmaceuticals Inc.

    (Title of Class of Securities)

    Common Shares, without par value

    (CUSIP Number)

    98420N105

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 98420N105
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,178,324
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,178,324
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,178,324
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.9%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 98420N105
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,178,324
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,178,324
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,178,324
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.9%
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 98420N105
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              177
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       177
     
    (9) Aggregate amount beneficially owned by each reporting person
    177
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 98420N105
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,178,501
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,178,501
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,178,501
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.9%
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:

    Xenon Pharmaceuticals Inc.

    Item 1(b) Address of issuer's principal executive offices:

    200-3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to common shares, without par value (“Shares”), of the Issuer held
    by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors
    Inc.”) with respect to Shares held by an investment fund managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with
    respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen
     (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management,
    Point72 Capital Advisors Inc., and Cubist Systematic Strategies.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902;
    and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Common Shares, without par value

    2(e) CUSIP Number:

    98420N105

    Item 3.

    Not applicable



    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management
    agreement, Point72 Asset Management maintains investment and voting power with respect to
    the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist
    Systematic Strategies maintains investment and voting power with respect to the securities held
    by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Cubist Systematic Strategies.  The filing of this statement
    should not be construed as an admission that any of the foregoing persons or any reporting
    person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported
    herein.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a)

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect.



    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.
    Dated: February 14, 2023
    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    Get the next $XENE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENE

    DatePrice TargetRatingAnalyst
    2/24/2026$60.00Outperform
    Wolfe Research
    9/3/2025$48.00Overweight
    Wells Fargo
    5/7/2025$55.00Buy
    Chardan Capital Markets
    2/11/2025$67.00Buy
    Deutsche Bank
    10/10/2024$50.00Outperform
    Raymond James
    10/1/2024$53.00Buy
    H.C. Wainwright
    1/4/2024$62.00Buy
    Citigroup
    12/8/2023$63.00Outperform
    Robert W. Baird
    More analyst ratings

    $XENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

    VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded w

    3/12/26 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

    VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a

    3/10/26 10:39:32 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Announces Proposed Public Offering

    VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offer

    3/9/26 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Xenon Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $60.00

    2/24/26 7:57:17 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Xenon Pharmaceuticals with a new price target

    Wells Fargo resumed coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $48.00

    9/3/25 8:41:10 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xenon Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00

    5/7/25 8:39:12 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Kenney Christopher John converted options into 3,750 shares and sold $77,867 worth of shares (1,410 units at $55.23), increasing direct ownership by 49% to 7,069 units (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    3/13/26 8:16:56 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Difabio Andrea sold $74,112 worth of shares (1,342 units at $55.22) and converted options into 3,750 shares, increasing direct ownership by 49% to 7,301 units (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    3/13/26 8:16:43 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CEO Mortimer Ian converted options into 12,500 shares and sold $403,584 worth of shares (7,308 units at $55.23), increasing direct ownership by 35% to 19,923 units (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    3/13/26 8:16:26 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    SEC Filings

    View All

    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    3/13/26 4:10:58 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Entry into a Material Definitive Agreement

    8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    3/12/26 4:17:51 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Xenon Pharmaceuticals Inc.

    FWP - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    3/10/26 9:23:29 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Financials

    Live finance-specific insights

    View All

    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

    X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00

    3/9/26 7:00:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

    VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information:  Date:Monday, March 9, 2026  Time:8:00 am ET (5:00 am PT)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:78

    3/8/26 2:00:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Reports Third Quarter 2025 Financial Results & Business Update

    – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera

    11/3/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Leadership Updates

    Live Leadership Updates

    View All

    Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

    VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team. Mr. Kelly is a proven executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner. Azetukalner is currently being studi

    10/16/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

    VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company's portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the trea

    6/24/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

    – OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against

    12/6/24 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    11/12/24 10:40:28 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 9:12:03 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 7:43:11 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care